JP2017537927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537927A5 JP2017537927A5 JP2017529805A JP2017529805A JP2017537927A5 JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5 JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- synergistic
- administered
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087489P | 2014-12-04 | 2014-12-04 | |
| US62/087,489 | 2014-12-04 | ||
| PCT/US2015/063585 WO2016090070A1 (en) | 2014-12-04 | 2015-12-03 | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537927A JP2017537927A (ja) | 2017-12-21 |
| JP2017537927A5 true JP2017537927A5 (enExample) | 2019-01-17 |
Family
ID=55022696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529805A Withdrawn JP2017537927A (ja) | 2014-12-04 | 2015-12-03 | がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170355768A1 (enExample) |
| EP (1) | EP3227335A1 (enExample) |
| JP (1) | JP2017537927A (enExample) |
| KR (1) | KR20170088984A (enExample) |
| CN (1) | CN107249632A (enExample) |
| AU (1) | AU2015358462A1 (enExample) |
| BR (1) | BR112017011538A2 (enExample) |
| CA (1) | CA2969665A1 (enExample) |
| EA (1) | EA201791049A1 (enExample) |
| IL (1) | IL252535A0 (enExample) |
| MX (1) | MX2017007097A (enExample) |
| SG (1) | SG11201704343SA (enExample) |
| WO (1) | WO2016090070A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013015000A2 (pt) | 2010-12-17 | 2016-08-09 | Novartis Ag | formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina |
| WO2012149356A2 (en) | 2011-04-29 | 2012-11-01 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| EP3534951A4 (en) * | 2016-11-02 | 2020-09-23 | Apexigen, Inc. | ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES |
| WO2019200462A1 (en) * | 2018-04-16 | 2019-10-24 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| DK2112166T3 (en) | 1998-12-23 | 2019-02-04 | Pfizer | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| SK287200B6 (sk) | 1999-02-22 | 2010-03-08 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP2069478A2 (en) | 2006-08-07 | 2009-06-17 | PDL BioPharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| PT2068874E (pt) * | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
| JP2010500370A (ja) | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| KR20110096536A (ko) * | 2008-10-31 | 2011-08-30 | 애보트 바이오테라퓨틱스 코포레이션 | 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도 |
| WO2011053322A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| WO2011053321A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
-
2015
- 2015-12-03 US US15/531,538 patent/US20170355768A1/en not_active Abandoned
- 2015-12-03 CN CN201580065674.2A patent/CN107249632A/zh active Pending
- 2015-12-03 EP EP15816310.5A patent/EP3227335A1/en not_active Withdrawn
- 2015-12-03 BR BR112017011538A patent/BR112017011538A2/pt not_active IP Right Cessation
- 2015-12-03 WO PCT/US2015/063585 patent/WO2016090070A1/en not_active Ceased
- 2015-12-03 SG SG11201704343SA patent/SG11201704343SA/en unknown
- 2015-12-03 JP JP2017529805A patent/JP2017537927A/ja not_active Withdrawn
- 2015-12-03 AU AU2015358462A patent/AU2015358462A1/en not_active Abandoned
- 2015-12-03 CA CA2969665A patent/CA2969665A1/en not_active Abandoned
- 2015-12-03 EA EA201791049A patent/EA201791049A1/ru unknown
- 2015-12-03 MX MX2017007097A patent/MX2017007097A/es unknown
- 2015-12-03 KR KR1020177017909A patent/KR20170088984A/ko not_active Withdrawn
-
2017
- 2017-05-25 IL IL252535A patent/IL252535A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537927A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| JP2019526595A5 (enExample) | ||
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| JP2015532292A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2016530280A5 (enExample) | ||
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| JP2009518441A5 (enExample) | ||
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| JP2018503610A5 (enExample) | ||
| AR105027A1 (es) | Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos | |
| JP2012193216A5 (enExample) | ||
| RU2016151757A (ru) | Антагонисты pdl-1 и pd-1 для лечения hpv-отрицательных форм рака | |
| FI3464380T3 (fi) | Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma | |
| MX2020012755A (es) | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). | |
| JP2015517511A5 (enExample) | ||
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| JP2018522028A5 (enExample) | ||
| JP2018516936A5 (enExample) |